Table 1.
Characteristics of kidney allograft recipients
| Variables | N=92 patients |
|---|---|
| At the time of transplant | |
| Age (years), mean (SD) | 44 (15) |
| Women, N (%) | 37 (40) |
| Racial categories (Black), N (%) | 25 (27) |
| Cause of end stage kidney disease, N (%) | |
| Diabetes | 19 (21) |
| Hypertension | 18 (20) |
| Polycystic kidney disease | 6 (7) |
| IgA nephropathy | 5 (5) |
| Lupus nephritis | 5 (5) |
| Focal and segmental glomerulosclerosis | 4 (4) |
| Other glomerular diseases | 9 (10) |
| Others or Unknown | 26 (28) |
| Deceased donor organ, N (%) | 48 (52) |
| Cold ischemia time, hours, deceased donor, mean (SD) | 26 (10) |
| Human leukocyte antigen mismatches, mean (SD) | 5 (2) |
| Donor information available, N (%) | 73 (79) |
| Age (years), mean (SD) | 44 (15) |
| Women, N (%) | 38 (52) |
| Racial categories (black), N (%) | 13 (18) |
| Previous transplants, N (%) | 16 (17) |
| Panel Reactive antibodies (PRA)a, Data available, N (%) | 69 (73) |
| Peak PRA %, median (IQR) | 11 (0–100) |
| Pre-transplant PRA %, median (IQR) | 0 (0–80) |
| CDC cross match, Data available, N (%) | 92 (100) |
| T-cell positive, N (%) | 0 (0) |
| B-cell positive, N (%) | 10 (11) |
| Flow Cytometry cross match, Data available, N (%) | 30 (33) |
| T-cell positive | 11 (37) |
| B-cell positive | 14 (47) |
| Luminex platform DSA, Data available, N (%) | 17 (18) |
| DSA negative (MFI of the highest rank donor-specific bead <1000) | 11 (65) |
| DSA positive (MFI of the highest rank donor-specific bead >1000 | 6 (35) |
| Received desensitization therapy, N (%) | 15 (16) |
| Induction Immunosuppression, N (%) | 62 (67) |
| Antithymocyte globulin | 54 (87) |
| Interleukin receptor-2 antibodies | 8 (13) |
| After transplant and before the index allograft biopsy | |
| Delayed graft function, N (%) | 15 (16) |
| Calcineurin inhibitor based maintenance immunosuppression, N (%) | 89 (97) |
| Early corticosteroid withdrawal | 39 (42) |
| Thrombotic microangiopathy, N (%) | 4 (4) |
| Hepatitis C virus, N (%) | 15 (16) |
| Acute rejection, N (%) | 23 (25) |
| Acute rejection episodes, N | 28 |
| Acute T-cell mediated rejection episodes, N (%) | 13 (46) |
| Acute antibody-mediated rejection episodes, N (%) | 7 (25) |
| Mixed acute T-cell and antibody-mediated rejection episodes, N (%) | 8 (29) |
| At the time of index allograft biopsy | |
| Age, mean (SD) | 48 (14) |
| Time from transplantation to biopsy (months), median (IQR) | 43 (16–83) |
| Luminex platform DSA, Data available, N (%) | 37 (40) |
| DSA negative (MFI of the highest rank donor-specific bead <1000) | 11 (30) |
| DSA positive (MFI of the highest rank donor-specific bead >1000) | 26 (70) |
| Serum creatinine (mg/dl), median (IQR) | 2.75 (2.15–4.14) |
| Proteinuria >1 g/day, N (%) | 63 (68) |